Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regenxbio

6.29
-0.3800-5.70%
Post-market: 6.290.00000.00%19:49 EDT
Volume:1.09M
Turnover:6.93M
Market Cap:315.04M
PE:-1.37
High:6.55
Open:6.45
Low:6.26
Close:6.67
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h

Regenxbio downgraded to Neutral from Buy at Goldman Sachs

TIPRANKS
·
11 Feb

Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet

Zacks
·
10 Feb

With 71% ownership of the shares, REGENXBIO Inc. (NASDAQ:RGNX) is heavily dominated by institutional owners

Simply Wall St.
·
04 Feb

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

PR Newswire
·
30 Jan

Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?

Zacks
·
24 Jan

REGENXBIO Price Target Maintained With a $30.00/Share by RBC Capital

Dow Jones
·
21 Jan

REGENXBIO Price Target Maintained With a $36.00/Share by HC Wainwright & Co.

Dow Jones
·
15 Jan

Regenxbio Shares up 3.6% on Partnership With Japan's Nippon Shinyaku for Gene Therapies

THOMSON REUTERS
·
14 Jan

Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday

MT Newswires Live
·
14 Jan

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as Traders Brace for Inflation Report

MT Newswires Live
·
14 Jan

BUZZ-Regenxbio rises on partnership with Japan's Nippon Shinyaku

Reuters
·
14 Jan

REGENXBIO, Nippon Shinyaku Partner to Advance Drug Candidates for Certain Genetic Disorders in US, Asia

MT Newswires Live
·
14 Jan

Regenxbio Inc - Retains Rights to Rgx-121 Priority Review Voucher

THOMSON REUTERS
·
14 Jan

Regenxbio and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize Rgx-121 and Rgx-111 for Mps Diseases

THOMSON REUTERS
·
14 Jan

Regenxbio Inc - to Receive $110 Million Upfront, up to $700 Million in Milestones

THOMSON REUTERS
·
14 Jan

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

PR Newswire
·
14 Jan

Abbvie: Pivotal Data Evaluating Safety and Efficacy of Subretinal Delivery of Abbv-Rgx-314 in Wet Amd Expected in 2026

THOMSON REUTERS
·
13 Jan

Abbvie: Will Plan Phase 3 Clinical Program of Investigational Abbv-Rgx-314 in Diabetic Retinopathy

THOMSON REUTERS
·
13 Jan

Regenxbio price target lowered to $22 from $25 at BofA

TipRanks
·
08 Jan

RBC Lowers Price Target on REGENXBIO to $30 From $35, Keeps Outperform, Speculative Risk

MT Newswires Live
·
07 Jan

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."